CY1119118T1 - Θεραπευτικος παραγων για τις διαταραχες της διαθεσης - Google Patents
Θεραπευτικος παραγων για τις διαταραχες της διαθεσηςInfo
- Publication number
- CY1119118T1 CY1119118T1 CY20171100798T CY171100798T CY1119118T1 CY 1119118 T1 CY1119118 T1 CY 1119118T1 CY 20171100798 T CY20171100798 T CY 20171100798T CY 171100798 T CY171100798 T CY 171100798T CY 1119118 T1 CY1119118 T1 CY 1119118T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- therapeutic products
- prophylaxis
- agent
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Παρέχονται ένας παράγων για την αγωγή και/ή την προφύλαξη μίας διαταραχής της διάθεσης ο οποίος περιλαμβάνει, ως δραστικό συστατικό, ένα παράγωγο του θειαζολίου που αναπαριστάται από τον τύπο (I) όπου το R1 αναπαριστά αρύλιο ή παρόμοιο, και το R2 αναπαριστά πυριδύλιο ή παρόμοιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτού, και παρόμοια.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009202893 | 2009-09-02 | ||
| PCT/JP2010/064988 WO2011027805A1 (ja) | 2009-09-02 | 2010-09-02 | 気分障害治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119118T1 true CY1119118T1 (el) | 2018-02-14 |
Family
ID=43649339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100798T CY1119118T1 (el) | 2009-09-02 | 2017-07-26 | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9249135B2 (el) |
| EP (1) | EP2474543B1 (el) |
| JP (1) | JP5663484B2 (el) |
| KR (1) | KR101762981B1 (el) |
| CN (1) | CN102482272A (el) |
| AU (1) | AU2010290423B2 (el) |
| BR (1) | BR112012004851B8 (el) |
| CA (1) | CA2772920C (el) |
| CL (1) | CL2012000534A1 (el) |
| CY (1) | CY1119118T1 (el) |
| DK (1) | DK2474543T3 (el) |
| DO (1) | DOP2012000058A (el) |
| EA (1) | EA030333B1 (el) |
| ES (1) | ES2633538T3 (el) |
| GE (1) | GEP20156224B (el) |
| HR (1) | HRP20171137T1 (el) |
| HU (1) | HUE033690T2 (el) |
| IL (1) | IL218321A (el) |
| LT (1) | LT2474543T (el) |
| MA (1) | MA33618B1 (el) |
| ME (1) | ME02804B (el) |
| MX (1) | MX2012002528A (el) |
| NZ (1) | NZ598750A (el) |
| PL (1) | PL2474543T3 (el) |
| PT (1) | PT2474543T (el) |
| RS (1) | RS56345B1 (el) |
| SI (1) | SI2474543T1 (el) |
| TN (1) | TN2012000092A1 (el) |
| UA (1) | UA110097C2 (el) |
| WO (1) | WO2011027805A1 (el) |
| ZA (1) | ZA201202346B (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3002283T (lt) * | 2003-12-26 | 2017-09-11 | Kyowa Hakko Kirin Co., Ltd. | Tiazolo dariniai |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| MA41090A (fr) * | 2014-12-03 | 2017-10-10 | H Lundbeck As | Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson |
| JOP20200093A1 (ar) | 2015-01-09 | 2017-06-16 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| JP2021528398A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール |
| CA3103932A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of roryt |
| CA3103770A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| WO2019243999A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69331843T2 (de) | 1992-07-08 | 2002-09-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine-Derivate als Antidepressiva |
| ATE325610T1 (de) | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| US20030139395A1 (en) | 2001-09-13 | 2003-07-24 | Schering Corporation | Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic |
| US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| CN1787821A (zh) | 2003-06-10 | 2006-06-14 | 协和发酵工业株式会社 | 一种治疗焦虑症的方法 |
| LT3002283T (lt) | 2003-12-26 | 2017-09-11 | Kyowa Hakko Kirin Co., Ltd. | Tiazolo dariniai |
| EP1730122A2 (en) | 2004-03-30 | 2006-12-13 | Taisho Pharmaceutical Co., Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1894930A4 (en) * | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
| TWI457125B (zh) | 2005-08-02 | 2014-10-21 | 睡眠障礙之治療劑 |
-
2010
- 2010-02-09 UA UAA201203928A patent/UA110097C2/uk unknown
- 2010-09-02 PT PT108137530T patent/PT2474543T/pt unknown
- 2010-09-02 EP EP10813753.0A patent/EP2474543B1/en active Active
- 2010-09-02 WO PCT/JP2010/064988 patent/WO2011027805A1/ja active Application Filing
- 2010-09-02 JP JP2011529926A patent/JP5663484B2/ja not_active Expired - Fee Related
- 2010-09-02 CN CN2010800392296A patent/CN102482272A/zh active Pending
- 2010-09-02 RS RS20170748A patent/RS56345B1/sr unknown
- 2010-09-02 AU AU2010290423A patent/AU2010290423B2/en not_active Ceased
- 2010-09-02 PL PL10813753T patent/PL2474543T3/pl unknown
- 2010-09-02 US US13/393,035 patent/US9249135B2/en not_active Expired - Fee Related
- 2010-09-02 ES ES10813753.0T patent/ES2633538T3/es active Active
- 2010-09-02 NZ NZ598750A patent/NZ598750A/en not_active IP Right Cessation
- 2010-09-02 ME MEP-2017-168A patent/ME02804B/me unknown
- 2010-09-02 MX MX2012002528A patent/MX2012002528A/es active IP Right Grant
- 2010-09-02 LT LTEP10813753.0T patent/LT2474543T/lt unknown
- 2010-09-02 KR KR1020127008307A patent/KR101762981B1/ko active IP Right Grant
- 2010-09-02 EA EA201270359A patent/EA030333B1/ru unknown
- 2010-09-02 CA CA2772920A patent/CA2772920C/en not_active Expired - Fee Related
- 2010-09-02 SI SI201031510T patent/SI2474543T1/sl unknown
- 2010-09-02 DK DK10813753.0T patent/DK2474543T3/en active
- 2010-09-02 HU HUE10813753A patent/HUE033690T2/hu unknown
- 2010-09-02 GE GEAP201012647A patent/GEP20156224B/en unknown
- 2010-09-02 BR BR112012004851A patent/BR112012004851B8/pt not_active IP Right Cessation
-
2012
- 2012-02-26 IL IL218321A patent/IL218321A/en active IP Right Grant
- 2012-02-27 TN TNP2012000092A patent/TN2012000092A1/en unknown
- 2012-02-29 CL CL2012000534A patent/CL2012000534A1/es unknown
- 2012-03-01 DO DO2012000058A patent/DOP2012000058A/es unknown
- 2012-03-30 MA MA34733A patent/MA33618B1/fr unknown
- 2012-03-30 ZA ZA2012/02346A patent/ZA201202346B/en unknown
-
2017
- 2017-07-21 HR HRP20171137TT patent/HRP20171137T1/hr unknown
- 2017-07-26 CY CY20171100798T patent/CY1119118T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119118T1 (el) | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης | |
| CY1123569T1 (el) | Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CY1124652T1 (el) | Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες | |
| CY1121144T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| CY1119488T1 (el) | Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
| CR20140052A (es) | Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| MX2015015168A (es) | Derivados heterociclicos y sus usos. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
| UA109793C2 (uk) | Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс) | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| NZ626112A (en) | Triazinone compound and t-type calcium channel inhibitor | |
| NZ707832A (en) | 2-pyridone compound | |
| CY1115153T1 (el) | Μεθοδοι για την αγωγη δερματολογικων διαταραχων |